Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III study of SPK-8011 for hemophilia A

Next Previous
Trial Profile

A Phase III study of SPK-8011 for hemophilia A

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jul 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 12 Jul 2020 According to a Spark Therapeutics media release, dosing participants in this Phase 3 stduy is expected to occur in 2021.
  • 19 Feb 2019 Status changed from planning to recruiting, according to the Spark Therapeutics media release.
  • 02 Dec 2018 According to a Spark Therapeutics media release, the company intends to initiate this phase 3 run-in study by the end of 2018 to collect prospective observational data on trial participants.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top